How I treat elderly patients with diffuse large B-cell lymphoma

Blood

Volumn 116, Issue 24, 2010, Pages 5103-5110

  Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BENDAMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FATIGUE; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; VALIDITY; WORLD HEALTH ORGANIZATION;

EID: 78650066026     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-259333     Document Type: Review

References (71)

1. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia. Canberra, Australia: Australian Institute of Health and Welfare; 2003.
2. World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland: WHO Press; 2008.
3. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology, but not the immunohistochemical GCB/non-GCB classfier, predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial [published online ahead of print August 24, 2010]. Blood. doi 10.1182/blood-2010-03-276766.
4. Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin- Frankfurt-Munster) Multicenter Trial. Blood. 2006; 107(10):4047-4052.
5. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13(17):5124-5132.
6. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110(3): 972-978.
7. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. 2008;22(12): 2226-2229.
8. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol. 2009;40(5): 645-652.
9. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.
11. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27(33):5573-5579.
12. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-812.
13. Rimsza LM, LeBlanc ML, Unger JM, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2008;112(8): 3425-3433.
14. Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34(1):60-67.
15. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14): 987-994.
16. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5): 1857-1861.
17. + B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
18. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556-562.
19. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymph. 2006; 47(10):2174-2180.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
21. Wedding U, Roehrig B, Klippstein A, et al. Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol. 2007;61(3):269-276.
22. Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol. 2010;28(12):2046-2050.
23. Hamlin PA. Treatment of aggressive non-Hodgkin and Hodgkin's lymphoma in older patients. ASCO Ed Book. 2007:295-299.
24. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998-2005.
25. Siegel AB, Lachs M, Coleman M, Leonard JP. Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymph Myeloma. 2006; 7(1):65-69.
26. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634-641.
27. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
28. Miller TP, Unger JM, Spier C, et al. Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014) [abstract]. Blood. 2004;104:48a.
29. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited- stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258-2263.
30. Sehn LH, Savage KJ, Hoskins P, et al. Limited-stage diffuse large B-cell lymphoma patients with a negative PET scan following three cycles of R-CHOP can be effectively treated with abbreviated chemoimmunotherapy alone [abstract]. Blood. 2007;110:242a.
31. Pfreundschuh M, Truemper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
32. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non- Hodgkin's lymphoma. J Clin Oncol. 2009;27(15s): 435s.
33. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914-2924.
34. Pfreundschuh M, Ziepert M, Reiser M, et al. The role of radiotherapy to bulky disease in the rituximab era: results from two prospective tirals of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood. 2008; 112(11):219a.
35. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEJM. 2002;346(4):235-242.
36. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127.
37. Pfreundschuh M, Zeynalova S, Poeschel V, et al. Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense Rituximab: results of the DENSE-R-CHOP-14 trial of the German High- Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2008;19(suppl 4):iv99.
38. Pfreundschuh M, Murawski N, Zeynalova S, et al. Male sex is associated with lower rituximab trough serum levels and evolves as a significant prognostic factor in elderly patients with DLBCL treated with R-CHOP: results from 4 prospective trials of the German High-Grade Non-Hodgkin- Lymphoma Study Group (DSHNHL) [abstract]. Blood. 2009;114:1431a.
39. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.
40. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16(7):1160-1168.
41. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514-1523.
42. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107(11):2678-2687.
43. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376-1381.
44. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20(2):309-318.
45. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma [abstract]. Blood. 2008;112:144a.
46. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced- stage diffuse large B-cell lymphoma. J Clin Oncol. 2010;28(11):1896-1903.
47. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10): 1626-1632.
48. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
49. Hartmann F, Zeynalova S, Nickenig C, et al. PEG-filgrastim (PEG-F) on day 4 of (R-)CHOP-14 chemotherapy is superior to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of a randomized trial of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) [abstract]. J Clin Oncol. 2007; 25:707s.
50. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-3902.
51. Herbert K, Wolf M, Carney D, et al. The addition of systemic high-dose methotrexate (HD-MTX) to intrathecal chemotherapy (IT) for central nervous system prophylaxis substantially reduces CNS recurrence rates in patients with at-risk aggressive lymphoma: a historically controlled prospective study [abstract]. Blood. 2008;112:1230.
52. Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000;35(3):147-154.
53. Balducci L, Extermann M. Management of the frail person with advanced cancer. Crit Rev Oncol Hematol. 2000;33(2):143-148.
54. Balducci L. Aging, frailty, and chemotherapy. Cancer Contr. 2007;14(1):7-12.
55. Balducci L. Supportive care in elderly cancer patients. Curr Opin Oncol. 2009;21(4):310-317.
56. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927-1932.
57. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy- sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
58. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998;16(10):3264-3269.
59. Gisselbrecht C, Glass B, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation [abstract]. J Clin Oncol. 2009;27:436s.
60. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12(12):1326-1334.
61. Glass B, Nickelsen M, Dreger P, et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant. 2004;34(5):391-397.
62. Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplantation in lymphoma: current status. Haematologica. 2007;92(11):1533-1548.
63. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]-tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25(11):1396-1402.
64. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine, and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363-1368.
65. Lopez A, Gutierrez A, Palacios A, et al. GEMOX- R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008;80(2):127-132.
66. Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/ relapsing B-cell lymphoma. Cancer Chemother Pharmacol. 2009;64(5):907-916.
67. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
68. Schmitz N, Nickelsen M, Ziepert M, et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trail if the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]. Blood. 2009; 114:168s.
69. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(22):5044-5051.
70. Leonard J, Friedberg J, Younes A. Results from a phase I/II study of galiximab (anti-CD80) in combination with rituximab (anti-CD20) for relapsed or refractory follicular NHL [abstract]. Ann Oncol. 2005;16(suppl):v71.
71. Murawski N, Pfreundschuh M. New drugs for aggressive B- and T-cell lymphomas. Lancet Oncol. 2010; in press.